KOAH Bülteni 2013 Sayı 2

literatür özetleri
19. Luo X, Pietrobon R, Sun SX, Liu GG, Hey L. Estimates
and patterns of direct health care expenditures
among individuals with back pain in the United States.
Spine 2004;29:79–86.
20. Berner T, Thomson H, Hartry A, Puenpatom RA,
Ben-Joseph R, Szeinbach SL. A comparison of daily
average consumption of oxycodone controlled release
(oxycontin CR) and oxymorphone extended release
(opana ER) in patients with low back pain. P T
2011;36:139–144.
21. Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan
Braden J, Martin BC. Trends in use of opioids for
non-cancer pain conditions 2000-2005 in commercial
and Medicaid insurance plans: the TROUP study. Pain
2008;138:440–449.
22. Boling MC, Padua DA, Marshall SW, Guskiewicz K,
Pyne S, Beutler A. A prospective investigation of biomechanical
risk factors for patellofemoral pain syndrome:
the Joint Undertaking to Monitor and Prevent
ACL Injury (JUMP-ACL) cohort. Am J Sports Med
2009;37:2108–2116.
23. Braden JB, Sullivan MD, Ray GT, Saunders K, Merrill
J, Silverberg MJ, et al. Trends in long-term opioid therapy
for noncancer pain among persons with a history
of depression. Gen Hosp Psychiatry 2009;31:564–570.
24. Clemens JQ, Meenan RT, O’Keeffe-Rosetti MC, Gao
SY, Brown SO, Calhoun EA. Prevalence of prostatitis-like
symptoms in a managed care population. J
Urol 2006;176:593–596, discussion 596.
25. Clemens JQ, Meenan RT, Rosetti MC, Gao SY, Calhoun
EA. Prevalence and incidence of interstitial cystitis in
a managed care population. J Urol 2005;173:98–102,
discussion 102.
26. Dominick KL, Ahern FM, Gold CH, Heller DA. Gender
differences in NSAID use among older adults with osteoarthritis.
Ann Pharmacother 2003;37:1566–1571.
27. Gore M, Tai KS, Sadosky A, Leslie D, Stacey BR. Clinical
comorbidities, treatment patterns, and direct
medical costs of patients with osteoarthritis in usual
care: a retrospective claims database analysis. J Media
Econ 2011;14:497–507.
28. Hermos JA, Young MM, Gagnon DR, Fiore LD. Characterizations
of long-term oxycodone/acetaminophen
prescriptions in veteran patients. Arch Intern Med
2004;164:2361–2366.
29. Khanna R, Smith MJ. Utilization and costs of medical
services and prescription medications for rheumatoid
arthritis among recipients covered by a state Medicaid
program: a retrospective, crosssectional,descriptive,
database analysis. Clin Ther 2007;29:2456–2467.
30. Morasco BJ, Dobscha SK. Prescription medication
misuse and substance use disorder in VA primary
care patients with chronic pain. Gen Hosp Psychiatry
2008;30:93–99.
31. Weir PT, Harlan GA, Nkoy FL, Jones SS, Hegmann
KT, Gren LH, et al. The incidence of fibromyalgia and
its associated comorbidities: a population-based
retrospective cohort study based on International
Classification of Diseases, 9th Revision codes. J Clin
Rheumatol 2006;12:124–128.
32. Berger A, Dukes EM, Oster G. Clinical characteristics
and economic costs of patients with painful neuropathic
disorders. J Pain 2004;5:143–149.
33. Solomon DH, Avorn J, Wang PS, Vaillant G, Cabral D,
Mogun H, et al. Prescription opioid use among older
adults with arthritis or low back pain. Arthritis Rheum
2006;55:35–41.
34. Ryder S-A, Stannard CF. Treatment of chronic pain:
antidepressant, antiepileptic and antiarrhythmic
drugs. Continuing Educ Anaesthesia Crit Care Pain
2005;5:18–21.
35. Lohne V, Heer HCD, Andersen M, Miaskowski C, Kongerud
J, Rustøen T. Qualitative study of pain of patients
with chronic obstructive pulmonary disease.
Heart Lung 2010;39:226–234.
36. Guest JF, Varney SJ, Diggle J. Impact of the British
Thoracic Society chronic obstructive pulmonary disease
guidelines on patients’ health status, healthcare
resource use and health-related quality of life. Prim
Care Respir J 2005;14:242–251.
37. Bentsen SB, Rustøen T, Miaskowski C. Differences
in subjective and objective respiratory parameters in
patients with chronic obstructive pulmonary disease
with and without pain. Int J Chron Obstruct Pulmon
Dis 2012;7:137–143.
38. Katsura H, Yamada K, Wakabayashi R, Kida K. Gender-associated
differences in dyspnoea and health-related
quality of life in patients with chronic
obstructive pulmonary disease. Respirology
2007;12:427–432.
39. Spencer S, Calverley PM, Sherwood Burge P, Jones
PW; ISOLDE Study Group. Inhaled Steroids in Obstructive
Lung Disease. Health status deterioration in
patients with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med 2001;163:122–128.
40. Rutten-van Molken MP, Oostenbrink JB, Tashkin DP,
Burkhart D, Monz BU. Does quality of life of COPD
patients as measured by the generic EuroQol five-dimension
questionnaire differentiate between COPD
severity stages? Chest 2006;130:1117–1128.
28